Chimerix CMRX 深 沪
等待开盘 12-19 09:30:00 美东时间
8.54
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 8.54
- 总市值 8.01亿
- 52周最高 8.55
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.75
- 委 比 0.00%
- 总股本 9380.38万
- 历史最高 58.04
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.75
- 每 手 1
- 风险率 2.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
Immix Biopharma公司宣布前Chimerix资深商业领导人Michael Grabow出任首席商务官，领导NXC-201在美国的上市及商业化进程。NXC-201针对复发性/难治性AL淀粉样变，此类疾病目前无FDA批准疗法。Michael Grabow拥有25年生物制药商业化经验，曾成功领导孤儿药MODEYSO®的上市。NXC-201获FDA授予再生医学先进疗法（RMAT）和罕见病药物认证（ODD），旨在解决该罕见病高未满足需求。
11-12 13:45
Creative Medical Technology Holdings Issues Letter to Shareholders
Creative Medical Technology Holdings, Inc. reported significant progress in 2025, advancing its regenerative immunotherapy platforms: AlloStem, ImmCelz, and iPScelz. The company is conducting Phase II trials targeting chronic lower back pain and Type 1 Diabetes, with expected 2026 results. Enhanced by recent patents and AI integration, Creative Medical aims to revolutionize regenerative medicine while maintaining financial discipline and strategi...
10-27 12:15
CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath
CorMedix Inc. announced that its DefenCath, an antimicrobial catheter lock solution, has received an Innovative Technology designation from Vizient. This recognition highlights DefenCath's potential to improve patient care and healthcare operations. DefenCath is FDA-approved to reduce catheter-related bloodstream infections in adult hemodialysis patients and has shown a 71% reduction in infection risk. CorMedix plans to expand access to the produ...
10-23 12:30
Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
<p>Clearmind Medicine Inc. has completed enrollment for the first cohort of its Phase I/IIa clinical trial for CMND-100, an oral drug candidate for treating Alcohol Use Disorder (AUD). Six patients were enrolled across sites at Johns Hopkins University School of Medicine and Yale School of Medicine. The trial assesses safety, tolerability, and pharmacokinetics, while exploring preliminary efficacy in reducing alcohol cravings and consumption. CEO...
10-21 11:25
CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team
CorMedix Inc. announced the completion of its acquisition of Melinta Therapeutics, expanding its portfolio with seven drug products and pipeline opportunities. The deal is expected to generate $325–$350 million in 2025 pro forma revenues and enhance profitability, with potential peak sales for REZZAYO™ prophylaxis exceeding $200 million. Key leadership roles have been finalized, and annual synergies are projected at $35–$45 million. The acquisiti...
09-02 11:30
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
DUBLIN, Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host an investor webcast on Wednesday, August 27, 2025, at 4:30 p.m. EDT / 9:30 p.m. IST to provide an over...
08-21 04:15
Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder
Clearmind Medicine Inc. announced the successful initiation of its Phase I/IIa clinical trial for CMND-100, a novel oral drug candidate targeting Alcohol Use Disorder (AUD), at Tel Aviv Sourasky Medical Center (TASMC). This trial, also conducted at leading US and Israeli institutions, evaluates CMND-100's safety, tolerability, and efficacy in reducing alcohol cravings and consumption. CMND-100, based on the molecule MEAI, has shown promise in pre...
07-23 12:55
Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
Clearmind Medicine Inc. expands its Phase I/IIa clinical trial for CMND-100, a psychedelic-derived drug for Alcohol Use Disorder (AUD), by adding Tel Aviv Sourasky Medical Center (TASMC) as a trial site. TASMC joins prestigious institutions like Yale and Johns Hopkins, strengthening the trial's capacity to evaluate CMND-100's safety and efficacy. The trial follows the enrollment of its first patient on June 5. Clearmind aims to address the global...
06-23 11:55
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study
Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients.
06-04 02:37
Chimerix Terminates Loan and Delists from Nasdaq
The latest announcement is out from Chimerix ( ($CMRX) ). On April 21, 2025, Ch...
04-22 04:52
